A novel chimeric antigen receptor T-cell therapy was developed by researchers in Germany and has been studied in preclinical tests as a potential treatment for chronic lymphocytic leukemia and follicular lymphomas, according to research in the journal Nature Communications. The approach sensitizes T cells to the B-cell homing protein CXCR5, which plays a role in B cells' movement from the bone marrow to organs such as lymph nodes and the spleen.
Investigative CAR T-cell therapy targets CXCR5 protein
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.